This provider averages 53 services per working day
Based on 66.7K total services over 5 years (250 working days/year). Learn about impossible service volumes →
This provider's $8.2M in total Medicare payments ranks in the 98th percentile of Ophthalmology providers nationally.
Averaging 53 services per working day raises questions about billing patterns.
Medicare payments to this provider grew 175023% from 2019 to 2023.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 11893% in 2021
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2019 | $1.4K | $175.43 | 7.99x | $1.2K | $2.3K | 13 | 1 |
| 2020 | $177.11 | $55.35 | 3.20x | $121.76 | $10.0K | 180 | 4 |
| 2021 | $257.47 | $196.28 | 1.31x | $61.19 | $1.2M | 6.1K | 19 |
| 2022 | $267.55 | $186.24 | 1.44x | $81.31 | $3.0M | 16.1K | 19 |
| 2023 | $127.56 | $90.15 | 1.41x | $37.41 | $4.0M | 44.3K | 23 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | 5.7K | $4.0M | $703.99 | 1.33x |
| J2778 | Injection, ranibizumab, 0.1 mg | 7.2K | $1.6M | $215.26 | 1.43x |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 26.7K | $769.1K | $28.81 | 1.35x |
| 67028 | Injection of drug into eye | 5.3K | $492.2K | $92.26 | 2.03x |
| 92014 | Established patient complete exam of visual system | 4.2K | $371.1K | $89.36 | 1.47x |
| 92134 | Imaging of retina | 10.4K | $316.4K | $30.57 | 1.39x |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 1.3K | $131.2K | $97.96 | 1.37x |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | 1.9K | $130.7K | $67.97 | 1.39x |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | 326 | $69.9K | $214.54 | 1.30x |
| 92004 | New patient complete exam of visual system | 516 | $54.8K | $106.15 | 1.47x |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | 81 | $40.8K | $503.85 | 1.59x |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | 43 | $35.4K | $824.22 | 1.56x |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | 254 | $31.1K | $122.47 | 1.44x |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | 196 | $30.8K | $157.39 | 1.28x |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | 255 | $30.7K | $120.36 | 1.33x |
| J9035 | Injection, bevacizumab, 10 mg | 466 | $25.0K | $53.58 | 1.71x |
| J3590 | Unclassified biologics | 132 | $22.7K | $171.68 | 1.31x |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | 130 | $12.6K | $96.86 | 1.33x |
| 67228 | Destruction of leaking blood vessels of retina using laser | 35 | $9.4K | $269.18 | 1.42x |
| 67145 | Photocoagulation treatment to prevent detachment of retina | 44 | $8.5K | $192.13 | 1.30x |
This provider submits charges 1.41 times higher than what Medicare actually pays.
A markup ratio of 1.41x means for every $100 Medicare pays, this provider initially charges $141. This is lower than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Ophthalmology providers in MI for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Sandeep Randhawa, MD | Royal Oak, MI | $44.6M | ✓ Clear |
| Scott Sneed, MD | Traverse City, MI | $39.4M | ✓ Clear |
| Jeremy Wolfe, MD | Royal Oak, MI | $39.4M | ✓ Clear |
| Douglas Covert, MD, MPH | Traverse City, MI | $34.7M | ✓ Clear |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data